论文信息 - Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. - 字舞流文

Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.

S. So | I. Klein | Y. Qian | R. Taub | J. Tilley | F. Mennona | C. Reynolds | S. Danzi | Kuo-Sen Huang | S. Pietranico-Cole | B. Banner | K. Conde-Knape | K. Thakkar | M. J. Kelly | M. Dvorozniak | N. Haynes | N. Scott | J. D. Larigan | J. Vermeulen | Martha J. Kelly | J. D. Larigan | Charles H. Reynolds | Je | erson Tilley